AmbuLatory Pediatric Asthma CAre
Reason given: refocus of business
Key facts
- Where
- Enschede, NetherlandsSee the site
Where in Netherlands
- MSTEnschede, NetherlandsNo longer taking part
Trial details
- Who runs it
- Philips Clinical & Medical Affairs Global
- Trial code
- NCT05517096
- Record updated
- 6 November 2024
- Original description
The ALPACA study has a prospective randomized control interventional design, including a follow-up period to evaluate follow-up effects. The study is divided into two phases of 3 months using eHealth and observational monitoring.Read full original descriptionShow less
ALPACA : the Effect of Online Monitoring and Communication on the Quality and Quantity of Pediatric Asthma Care
The ALPACA study has a prospective randomized control interventional design, including a follow-up period to evaluate follow-up effects. The study is divided into two phases of 3 months using eHealth and observational monitoring.
Inclusion: Children with moderate-to-severe asthma; Children in the age group from 4 up to and included 11 years old.
Exclusion: Prior participation in eHealth care trial; Children with chronic diseases other than asthma (i.e. inflammatory bowel disease, behavioral disorders, mental retardation); Currently displaying COVID-19-related symptoms, namely a fever, cough and/or difficulty breathing (during inclusion); Having been positively tested as infected with COVID-19 in the past 14 days; Children living in a house without WIFI; Children/Parents with an inability to understand or speak Dutch; Children with divorced parents or other reasons that causes them to be less than 80% on the same living address; Children of whom family members have already participated in this trial; Children for whom it is not possible to perform at least one of the two discontinuous dyspnea assessment (lung function/pulse oximetry); Children using an inhaler that is not compatible with the FindAir smart inhaler cap, which cannot be replaced by a compatible alternative.